02:13 PM EDT, 07/02/2024 (MT Newswires) -- (Updates with details throughout.)

Eli Lilly ( LLY ) said Tuesday the US Food and Drug Administration approved Kisunla for the treatment of adults with early symptomatic Alzheimer's disease.

The once-monthly treatment is shown to have slowed cognitive and functional decline by up to 35% in subjects and reduce the risk of participants progressing to the next clinical stage of disease by up to 39%, Lilly said in a statement, citing results from a late-stage study.

Kisunla works by targeting excessive buildup of so-called amyloid plaques that are linked with memory and thinking issues associated with Alzheimer's disease, according to Lilly.

Price: 908.40, Change: -5.97, Percent Change: -0.65